Introduction
Myogenesis is a multi-step process consisting of the determination of mesodermal precursor cells, myoblast migration and proliferation, cell fusion and terminal differentiation of myotubes. In vertebrates, all these steps are governed by sequential and compound activation of four myogenic regulatory factors (MRFs) that belong to the MyoD gene family: Myf5, MyoD, Mrf4 and myogenin (see Arnold and Braun, 1996) . Functions of these genes have been defined by analyses of their single, double and triple mutants in mice. Recent data show that Myf5 and Mrf4 play partially non-redundant roles in the determination of muscle identity and act upstream of MyoD (Kassar-Duchossoy et al., 2004) . In turn, function of MyoD significantly overlaps with functions of Myf5 and Mrf4. Double mutants of MyoD with either Myf5 or Mrf4 are characterized by an absence of skeletal muscles at birth (Rudnicki et al., 1993; Kassar-Duchossoy et al., 2004) . In mice lacking myogenin, myoblasts are specified and positioned correctly, but their fusion capacity is greatly impaired. This indicates that myogenin is critical for terminal differentiation of myoblasts (Hasty et al., 1993; Nabeshima et al., 1993) . Analysis of Myf5/MyoD double mutants with an intact Mrf4 gene revealed that skeletal myogenesis was absent in the head and, at later stages, severely compromised in the trunk, thus excluding a role for Mrf4 in the development of head muscles (Kassar-Duchossoy et al., 2004) . Apparently, Myf5, MyoD and myogenin are essential activators of the myogenic program that are required in virtually all striated muscles. In contrast to the well established role of MRFs for muscle development, much less is known about genes which have been proposed to act upstream of MRFs to determine early steps of myogenic lineage commitment.
Two members of the Pax family of transcriptional factors, Pax3 and Pax7, are supposed to be involved in the myogenic cell specification. Both genes are known as early markers of the forming dermomyotome, which is the source of future myoblasts (Goulding et al., 1991; Jostes et al., 1990) . The spontaneous Pax3 mutation, Splotch, when homozygous, is associated with the inability of myogenic precursors to migrate from somites into the growing limbs and the developing tongue and results in the complete absence of the respective muscles (Bober et al., 1994; Goulding et al., 1994; Tremblay et al., 1998) . Homozygous Pax7 knockout mice develop normally but the newborns show a slightly reduced muscle mass and most mutants survive only a few weeks (Mansouri et al., 1996; Oustanina et al., 2004) . Analysis of the affected muscles revealed a huge decrease of the number of satellite cells after birth indicating a role for Pax7 in satellite cell self-renewal (Seale et al., 2000; Oustanina et al., 2004) . Double knockouts of Pax3 and Pax7 resulted in a compromised development of somites and embryonic lethality at mid-gestation, suggesting a redundancy in functions of both genes during somitogenesis. In these compound mutant mice myotomal myogenesis is initiated but resident muscle progenitor cells do not follow the myogenic program (Relaix et al., 2005) . Evidence for a potential somitic and head myogenesis. Here, we present a systematic in situ analysis of spatiotemporal characteristics of Pax3 and Pax7 gene expression on the protein level during development of skeletal muscles of the trunk and head.
Results
Expression patterns of the Pax3, Pax7, MyoD and myogenin genes were analysed during mouse embryogenesis starting at stage E11.5 and in post-natal muscles. The respective proteins were immunohistochemically detected on adjacent paraffin sections using monoclonal antibodies, which were previously characterized as highly specific to the corresponding antigens. Expression of MyoD was considered as a marker of determined myoblasts, whereas myogenin-positive cells were judged as myoblasts that are more advanced in their differentiation (see introduction). In this study, we focused on the time course and spatial expression of Pax3 and Pax7 in respect to myogenic cells identified by their expression of MRFs.
Expression of Pax3 in developing muscles
Previously it was demonstrated on the RNA level that expression of Pax3 in the trunk region starts at E8.5, coinciding with involvement of Pax3 in myogenesis was also demonstrated by analysis of compound mutants of Pax3 and Myf5 (Tajbakhsh et al., 1997) . In the double homozygous embryos, skeletal muscle development in the trunk was missing, although the head muscles were essentially unaffected. The latter finding might be explained by a compensative role of Pax7 in the head myogenesis, although this possibility was excluded in the same study since expression of both genes in the head mesoderm was not detected at stage E10.5. In chicken embryos, however, Pax7 is expressed in at least one developing head muscle, the lateral rectus (Mootoosamy and Dietrich, 2002) . In this study, the rudiment of the largest extrinsic eye muscle was found to co-express Pax7 and an early somitic mesoderm marker Paraxis suggesting that in the cranial paraxial mesoderm Pax7 may work upstream of MRFs and substitute for Pax3.
Currently, it is not clear whether and to what extent Pax3 and/or Pax7 contribute to the progression of the myogenic process or whether they are involved in the development of head muscles. Skeletal muscles in the head and trunk are distinct in their origin. Most craniofacial muscles, except the tongue and laryngeal muscles, derive from the non-segmented prechordal and pre-otic mesoderm. Recent data indicate that distinct regulatory cascades operate in the head and trunk myogenesis that rely on either Pax3 or Pax7 (Hacker and Guthrie, 1998; Mootoosamy and Dietrich, 2002) . However, little is known about the normal time course and pattern of expression of these Pax genes in relation to the expression of MRFs in post-A B C segmentation of the mesoderm and begins to disappear at E11.5 during somite disintegration (Goulding et al., 1991) . To achieve a better understanding of the role of Pax3 at later stages of myogenesis we have focused our analysis on the expression of Pax3 from E11.5 onwards. At E11.5 Pax3-positive cells in the somites constituted the dermomyotome and delaminating myotome. However, only cells located within the myotome expressed MyoD and myogenin ( Fig. 1 A,B and data not shown). Not all cells in these structures were positive for either of these proteins. Pax3 was expressed in 79% (±5.5%) of all cells in the MyoD-positive areas. At E12.5, staining intensity for Pax3 did not decline, but Pax3-positive cells were found in a more diffuse allocation, constituting 56% (±4.6%) (Fig. 1C ). This pattern of distribution of Pax3-positive cells was observed in all MyoD-positive regions, which at this stage include pre-muscle masses in different positions in the trunk and in the limbs. These muscle anlagen are known to be formed by cells actively migrating out of the myotome. In addition, Pax3 was expressed in the hypoglossal cord, consisting of myoblasts migrating from the occipital trunk somites to the tongue ( Fig. 2) . At E13.5, some differentiated muscle fibers can be already distinguished by the tandem locations of the myogenin-positive nuclei. Starting at this time, most of the MyoDpositive areas were Pax3-negative, including muscles of the tongue and limbs ( Fig. 3 A,B and data not shown). However, in some muscle groups, e.g. those surrounding the sternum and located ventrally to the brown adipose tissue, a weak staining for Pax3 was observed in a few nuclei until E16.5 ( Fig. 3C) . At later stages, we did not detect Pax3-specific nuclear signals above background even after extended staining (data not shown). No Pax3 expression was detected at any stage in the MRFs-positive areas in the head (Figs. 2,4 and data not shown). In summary, the post-myotomal expression of Pax3 in the trunk was characterized by a restriction in cell number and complete disappearance in most of the differentiating muscles. Furthermore, expression of Pax3 was not detected in newborn and adult muscle tissues of the leg, trunk and head (Figs. 5,6 and data not shown). Similar results were obtained using polyclonal anti-Pax3 antibodies (data not shown).
To investigated a putative redundancy between Pax3 and Pax7 we also have analysed the expression of Pax3 in Pax7 knockout mice. Pax7-/-embryos were examined at E11.5 and E15.5, when Pax3 is expressed and not expressed in wild type embryos, respectively. The expression of Pax3 in the mutant embryos did not differ from its expression in wild type littermates (Fig. 6 A,B and data not shown) . In addition, we also did not find Pax3 protein in skeletal muscles of newborn and adult Pax7 -/-mice ( Fig. 6C and data not shown) .
Expression of Pax7 in developing muscles
It is well known that between E9-E11 the expression of Pax7 in the trunk largely overlaps with the expression of Pax3. During somitogenesis Pax7 is activated in the dermomyotome after Pax3 but before the onset of expression of MRFs (Jostes et al., 1990) . However, little is known about expression of Pax7 during myogenesis in the head. Previously, it has been reported that Pax7 was not expressed in the head mesenchyme at E10.5 (Tajbakhsh et al., 1997) . We also did not observe Pax7-positive cells in the head at this stage (data not shown). At E11.5, we detected Pax7 in cells of the MRFs-positive areas in the trunk and head mesenchyme. In the trunk, Pax7-positive cells marked the dermomyotome and myotome in a pattern very similar to Pax3 (Fig. 1A) . During the next stages the spatio-temporal expression of Pax7 resembled that of Pax3. In particular, we noted a decrease of the number of the Pax7-positive cells (Fig. 1B) . At E13.5, however, in contrast to Pax3, Pax7 was expressed in 35% (±3.3%) of all cells in MyoD-positive areas (Fig. 3A) . At later stages, the number of Pax7-positive cells declined further (Figs. 3B,4 and data not shown). However, it was difficult to quantify the Pax3 is expressed in migrating myoblasts, which constitute the hypoglossal cord but not in the muscle anlagen of the branchial arch. In contrast to Pax3, Pax7 is expressed in the developing muscles of the branchial arch. Note, that the premuscle mass penetrated by the trigeminal nerve is in a more advanced developmental stage compared to the distal muscle mass (a Pax7 positive nucleus shown in the magnified area) and to the extrinsic eye muscles (Fig. 7) and hence contains more Pax7-positive nuclei. HC, hypoglossal cord; OP, oropharynx; TG, trigeminal (V) ganglion.
remaining Pax7-positive cells due to their irregular distribution along the differentiated myofibers, which are not fully represented on the sections. A reverse pattern of Pax7 expression was observed during myogenesis in the head. In contrast to somites, where activity of Pax7 preceded expression of MRFs, in the head the MRFs were expressed prior to Pax7. At E11.5, MyoD and myogenin were found in small areas corresponding to the future extrinsic eye muscles (Fig. 7) and in muscle anlagen of the branchial arches, which are penetrated by nerves of the fifth cranial ganglion (Fig. 2) . Myogenin was present in fewer cells than MyoD within the respective areas, reflecting a later function in myogenesis. Expression of Pax7 just started at this stage and was found in a very small number of cells. Figure 7 shows that only few Pax7-positive nuclei were present on section No.2, compared to several MyoD and myogenin positive nuclei on sections No.1 and No.3, respectively. The order of sections excluded the possibility that fewer Pax7-positive nuclei were detected due to a marginal position of the section in respect to the MRFs-positive area. After E15.5, the spatial pattern of Pax7 expression in the developing cranial muscles was very similar to the situation in the trunk, epitopes, it can be excluded that the negative staining using the monoclonal antibody was due to masking of the epitope by a posttranslational modification.
Our observation that Pax3 is expressed only transiently during muscle development is not in agreement with recently published data, which postulate expression of Pax3 during pre-natal and post-natal myogenesis and even in satellite cells of adult mice (Relaix et al., 2005) . This apparent inconsistency might be explained by the different approaches used to detect Pax3 expression. We used a monoclonal antibody that recognizes Pax3 with a high affinity and produces no background allowing very sensitive antigen detection. The study by Relaix et al. (2005) is based on the detection of the green fluorescent protein (GFP) reporter targeted to the Pax3 gene. Obviously the artificial Pax3-GFP allele does not faithfully recapitulate expression of the endogenous Pax3 gene. It is possible that the integration of the GFP reporter gene resulted in silencing of control elements that are normally required for the down-regulation of Pax3. Alternatively, it might be envisioned that the GFP protein used to detect Pax3 expression is more stable than the actual Pax3 protein. where Pax7 was present in only a few cells within the MyoD-positive areas (Fig. 4 and data not shown). Pax7 was found only in mononucleated cells, the number of which declined with ongoing development. Costaining with anti-laminin antibodies revealed that Pax7 was present exclusively in the satellite cells of head and body muscles of newborn and adult mice (Figs 5,8 and data not shown).
Discussion

Pax3 is not associated with myogenic development after E13.5
The observed expression pattern of Pax3 suggests that the function of this gene is not associated with myogenesis in the head but transiently correlates with the beginning of muscle development in the trunk and limbs. In the head only the hypoglossal cord did contain cells that were positive for MRFs and Pax3. This structure, however, does not originate from the head but is formed by myoblasts that actively migrate from the occipital trunk somites to the tongue anlage. Muscles of the developing tongue were Pax3-negative. The post-somitic expression of Pax3 in the trunk and limbs was repressed in most muscles after E13.5. A very weak Pax3 signal, detected until E16.5 in rare nuclei of distinct muscle groups, might be explained by the different timing of the development of individual muscles. The negative staining for Pax3 in muscles at later stages was also corroborated using polyclonal anti-Pax3 antibodies. Since polyclonal antibodies recognize multiple 
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Pax3 is not de-repressed or re-activated in muscles of Pax7-/-mice
Pax3 -/-mutant embryos die at E13.5, due to multiple malformations including deformities of the heart, failure of the neural tube closure and lack those muscles, which develop from the migrating myoblast precursors (Tremblay et al., 1998) . Due to the early embryo lethality it is not possible to analyse whether Pax7 compensates for the absence of Pax3 in other developing muscles. On the other hand, muscle development in Pax7 -/-mutants was unaffected (Mansouri et al., 1996) . Although this finding might suggest a possible compensative role of Pax3 we did not find a compensatory up-regulation of Pax3 in muscles of Pax7 mutants making this possibility less likely.
Pax7 is uniformly expressed in muscles of the head and trunk
In contrast to Pax3, Pax7 is expressed in developing head muscles. Head and trunk muscles differ in their developmental origin. Muscles of the trunk derive from segmented somitic mesoderm. Cranial muscles (with the exception of the muscles of the tongue, which have a somitic origin) develop from pre-chordal and pre-otic nonsegmented mesoderm. There is experimental evidence that different regulatory cascades drive the initiation of myogenesis in the head and trunk (Hacker and Guthrie, 1998; Mootoosamy and Dietrich, 2002; Lu et al., 2002; Tzahor et al., 2003) . On the other hand, a recent transplantation study established that the head environment is able to support progressive differentiation of several distinct myogenic progenitor populations from the trunk (Borue and Noden, 2004) . In light of these data it was important to determine whether Pax7 is expressed in head muscle. As shown in Figure 5 , the onset of Pax7 expression followed the expression of MRF genes suggesting that Pax7 is not directly associated with the onset of myogenesis in the head 
Pax3, Pax7 and myogenesis
Several studies suggested a direct involvement of Pax3 and Pax7 in the myogenic process. A direct involvement of Pax3 in myogenesis has been suggested previously by experiments based on the ectopic expression of Pax3 in chicken embryos and the generation of Pax3/Myf5 double knockout mice (Maroto et al., 1997; Tajbakhsh et al., 1997) . The latter study demonstrated the absence of myogenesis in the trunk. However, re-examination of the original Pax3/Myf5 double knockout mice revealed that the double mutant was in fact a triple mutant, in which expression of the Mrf4 gene was additionally compromised. In fact, double knockouts of Pax3 and Myf5, in which Mrf4 is expressed regularly, seem to undergo normal myogenesis in the trunk (KassarDuchossoy et al., 2004) . At present it is unclear whether Pax3 is directly required to activate the MyoD gene in the absence of Myf5 as originally postulated (Tajbakhsh et al., 1997) or whether Pax3 provides a permissive environment for the enlargement of muscle precursor cell populations, which might increase the bias for myogenic differentiation and thus enable myogenic cells to respond to environmental cues (Mennerich and Braun, 2001 ). Pax3 has also been shown to direct the formation of limb muscles (Bober et al., 1994) . However, Pax3 is not directly linked to myogenesis in these cells. Transplantation experiments revealed that somites from Splotch embryos taken at stage E9.25 undergo that the core program of striated muscle development depends on Pax genes. Given the relatively short period of Pax3 expression in the trunk until stage E13.5 (in some muscles -until E16.5) it seems likely that the Pax3/7-cell population of muscle progenitors (Relaix et al., 2005) exists only transiently and does not constitute a persistent cell lineage. muscle differentiation when grafted into the limb bud of chick host embryos (Daston et al., 1996) . In double knockouts of Pax3 and Pax7 myotomal myogenesis is initiated and essentially normal until stage E13.5 further supporting the idea that Pax3 and Pax7 are not required for the induction of myogenesis (Relaix et al., 2005) . Our results also argue for a limited or indirect role of Pax genes for muscle development. Striated muscles are known to exhibit identical histology and physiology in the head and trunk, suggesting that realization of the myogenic programs is similar. A main difference between head and trunk muscles, however, is the mode of induction. Here, we have demonstrated that neither Pax7 nor Pax3 are likely to serve a role in the initiation of myogenesis in head muscles: (i) Pax3 is not expressed in head muscles; (ii) head muscle development is not affected in Pax7-/-and splotch mice; (iii) Pax7 is expressed only after expression of MRFs in head muscles. Moreover, Pax3 is not de-repressed in Pax7 -/-mice, in which muscle development proceeds normally, suggesting that after E13.5 myogenesis does not require Pax3 and Pax7. Taken together it seems not likely Based on these arguments it is tempting to speculate that Pax3 and Pax7 allow the formation of provisory myogenic structures, in which the myogenic process itself is initiated as a distinct program independent of Pax genes. Further experiments are required to reveal specific instructive roles of Pax3 and Pax7 for myogenesis.
Materials and Methods
Genotyping of the Pax7 knockout embryos
The generation of the Pax7-LacZ mutant mice has been published (Mansouri et al., 1996) . The mutant mice were maintained on a mixed 129Sv/C57/Bl6 background. Embryos were genotyped by PCR and Southern blot analysis, the absence of Pax7 protein was also corroborated by immunohistochemical stainings.
Immunohistochemistry
Embryos of wild type Balb/c mice were fixed in 4% paraformaldehyde and embedded into paraffin according to standard protocols. Adjacent 7 µm sections were used for comparative analysis. Endogenous peroxidase was inactivated in 0.3% H 2 O 2 in methanol. For antigen unmasking, the slides were autoclaved in 1 mM citrate buffer, pH 6.0. Immunodetection was performed with the primary mouse monoclonal antibodies anti-MyoD (DakoCytomation, Clone 5.8A), anti-myogenin (DakoCytomation, Clone F5D), anti-Pax3 developed by C. P. Ordahl and anti-Pax7 developed by A. Kawakami. The Pax3 and Pax7 antibodies were obtained from the Developmental Studies Hybridoma Bank (NICHD; The University of Iowa, Department of Biological Sciences, Iowa City, IA 52242). Rabbit polyclonal anti-Pax3 antibody was kindly provided by J. Epstein, University of Pennsylvania, Philadelphia, PA. The antibodies were applied with the following dilutions: 1:50 for anti-MyoD, 1:100 for anti-myogenin, 1:1000 for anti-Pax3 and anti-Pax7, 1:1000 for pre-absorbed polyclonal antiPax3. For detection of primary antibodies we used biotinylated rabbitanti-mouse antibody (DakoCytomation) and the avidin-biotin-complex (ABC, Vector). Anti-laminin rabbit polyclonal antibodies (L-9393, Sigma) were applied (1:200) after an additional unmasking treatment with proteinase K (Sigma), 100µg/ml, for 8 min at 37ºC. The anti-laminin antibodies were detected by donkey anti-rabbit-alkaline phosphatase conjugates (Dianova) and subsequent staining with the Fast Red alkaline phosphatase substrate (Sigma). Finally, the sections were counterstained with hematoxylin (DakoCytomation).
Cell quantification
Two embryos per stage were analysed. Cell counting was achieved using the Adobe Photoshop program. On a high magnification image of a selected area, positively stained nuclei were marked by dots and counted. The counting results were tested for consistency using a ChiSquare test (n=12, pα = 0.01). The differences between E11.5 and E12.5 and between E12.5 and E13.5 were shown to be significant (p-Test of binomial distributions; pα = 0.01), mean values were taken.
